Research / AHT / Fundamental state Inspectable configuration
State dimensions Filing 0001232582-23-000032 Reit
Debt 20th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.gross_debt
$3.8B · CORE · VALID
Revenue growth 55th Own-history percentile · N=11
Evidence method Yoy · gp.fundamentals.revenue
54.07% · CORE · VALID
Cash and equivalents 65th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.cash
$417.1M · CORE · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 26 states Self-history eligible
Sep 30, 2021 2/3 normalized Level 3 Dec 31, 2021 2/3 normalized Level 3 Mar 31, 2022 3/3 normalized Level 3 Jun 30, 2022 3/3 normalized Level 3 Sep 30, 2022 4/4 normalized Level 3 Dec 31, 2022 3/3 normalized Level 3 Mar 31, 2023 3/3 normalized Level 3 Jun 30, 2023 5/5 normalized Level 3 Sep 30, 2023 5/5 normalized Level 3 Dec 31, 2023 5/5 normalized Level 3 Mar 31, 2024 5/5 normalized Level 3 Jun 30, 2024 5/5 normalized Level 3 Sep 30, 2024 5/5 normalized Level 3 Dec 31, 2024 5/5 normalized Level 3 Mar 31, 2025 4/5 normalized Level 3 Jun 30, 2025 5/6 normalized Level 3 Sep 30, 2025 5/5 normalized Level 3 Dec 31, 2025 4/4 normalized Level 3 Mar 31, 2026 4/4 normalized Level 3 Jun 30, 2026 5/5 normalized Level 4 Period transition
What moved in the state? Debt Decreased
Previous $3.8B
Current $3.8B
Delta -$154,000 Growth Increased
Previous 32.62%
Current 54.07%
Delta 21.44% Liquidity Decreased
Previous $505.5M
Current $417.1M
Delta -$88.5M Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.